Department of Maxillofacial, Medical School, University Hospital of Ioannina, Ioannina, Greece.
J BUON. 2021 Sep-Oct;26(5):1719-1722.
Coronavirus-related Severe Acute Respiratory Syndrome (SARS-CoV) in 2002/2003, Middle-East Respiratory Syndrome (MERS-Cov) in 2012/2013, and especially the current 2019/2020 Severe Acute Respiratory Syndrome-2 (SARS-CoV-2) tested the national health systems' endurance worldwide. In order to fight this emergency situation, a variety of pharmaceutical companies focused on the design and development of efficient vaccines that are considered necessary for providing a level of normalization in totally affected human social-economical activity worldwide. COVID-19 led to an increased uncertainty in the field of oncological patients' management disrupting the normal conditions of therapeutic and monitoring procedures. In the current article, we explored the impact of SARS-CoV-2 infection on oral carcinoma patients. We observed COVD-19 pandemic negatively affects the normality regarding early diagnosis and optimal management (surgical operation, post-operational follow up/monitoring) in HNSCC/OSCC patients. Understanding the involvement of SARS-CoV-2 in the progression of malignancies is the first critical step for targeting the virus by efficient monoclonal antibodies and vaccines.
2002/2003 年的冠状病毒相关严重急性呼吸综合征(SARS-CoV)、2012/2013 年的中东呼吸综合征(MERS-Cov),特别是当前 2019/2020 年的严重急性呼吸综合征-2(SARS-CoV-2),在全球范围内考验了国家卫生系统的承受能力。为了应对这一紧急情况,许多制药公司专注于设计和开发高效疫苗,这被认为是为全球受影响的人类社会经济活动提供正常化水平所必需的。COVID-19 导致肿瘤患者管理领域的不确定性增加,扰乱了治疗和监测程序的正常状态。在本文中,我们探讨了 SARS-CoV-2 感染对口腔癌患者的影响。我们观察到 COVID-19 大流行对 HNSCC/OSCC 患者的早期诊断和最佳管理(手术、术后随访/监测)的正常状态产生负面影响。了解 SARS-CoV-2 在恶性肿瘤进展中的作用是通过高效单克隆抗体和疫苗靶向病毒的第一步关键步骤。